Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.39 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | GBA3 | Q9H227 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11110273 | 1.00 | CNR2 (0.39) | CNR2GBA1GBA3EPHX1 | |
| Phosphoric Acid SCHEMBL11084348 | 0.92 | S1PR4 (0.39) | CNR2 | |
| Phosphoric Acid SCHEMBL11090270 | 0.92 | S1PR4 (0.39) | CNR2 | |
| SCHEMBL11077870 | 0.89 | GBA1 (0.36) | CNR2GBA1GBA3EPHX1 | |
| SCHEMBL15271184 | 0.83 | THRB (0.36) | EPHX1 | |
| SCHEMBL15270868 | 0.83 | THRB (0.36) | EPHX1 | |
| SCHEMBL15271964 | 0.83 | THRB (0.36) | EPHX1 | |
| SCHEMBL9691529 | 0.83 | THRB (0.36) | EPHX1 | |
| SCHEMBL15271306 | 0.83 | THRB (0.36) | EPHX1 | |
| SCHEMBL15271259 | 0.83 | THRB (0.36) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106032-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | disclosed |
| EP-0781138-B1 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | UNIV WAKE FOREST (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7294621-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294620-B2 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294619-B2 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1852121-A2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-20070105811-A1 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-20070099870-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY | 2007-05-03 | — | — | US | disclosed |
| US-7141557-B2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-11-28 | — | — | US | disclosed |
| US-7135584-B2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7129227-B1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050080050-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040259845-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY | 2004-12-23 | — | — | US | disclosed |
| US-5962437-A | HEPATITIS, HERPES AND AIDA VIRUS | WAKE FOREST UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0781138-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996006620-A2 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | WAKE FOREST UNIVERSITY (US) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | SGMS1, HDLBP, LIPC | CNR2 3037/4885GBA1 152/4885GBA3 270/4885 |
| US-20070105811-A1 | Lipid analogs for inhibiting the activity of hepatitis B antigen | LIPC, APOB, PNLIP | CNR2 2701/4885GBA1 94/4885GBA3 139/4885 |
| US-20040259845-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | CNR2 2369/4885GBA1 89/4885GBA3 357/4885 |
| US-20050080050-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | CNR2 2369/4885GBA1 89/4885GBA3 357/4885 |
| US-20080293667-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | CNR2 2000/4885GBA1 136/4885GBA3 429/4885 |
| US-20070099870-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | CNR2 2000/4885GBA1 136/4885GBA3 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.